Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC Cambridge, UK Wednesday, June 25, 2025, 09:00 Hrs [IST] Datroway (datopotamab ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

AstraZeneca and its partner Daiichi Sankyo have won approval from US regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Pharma AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset By Kevin Dunleavy Jun 24, 2025 8:10am Datroway Daiichi Sankyo AstraZeneca antibody-drug conjugates ...

Following approval in the US, AstraZeneca is required to pay $45 million to Daiichi Sankyo as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication.

Datroway is an ADC to treat non-small cell lung cancer. Credit: Saiful52/Shutterstock. The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo’s Datroway (Datopotamab ...

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the ...

Japan has started releasing wastewater into the ocean. But this isn’t the kind of wastewater that flows from city streets into stormwater drains. It’s treated nuclear wastewater used to cool ...

Review the current valuation for Daiichi Sankyo Co Ltd (4568:XTKS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo ...